Polyclonal Antibody to Colony Stimulating Factor Receptor, Granulocyte (GCSFR)
Code | Size | Price |
---|
PAB476Hu02-20ul | 20ul | £84.00 |
Quantity:
PAB476Hu02-100ul | 100ul | £155.00 |
Quantity:
PAB476Hu02-200ul | 200ul | £208.00 |
Quantity:
PAB476Hu02-1ml | 1ml | £475.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD114; G-CSFR; CSF3R; CSF3-R; GCSF-R
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Colony Stimulating Factor Receptor, Granulocyte
Reactivity:
Mu;Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 1-5ug/mL<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/mL<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL<br/>Immunohistochemistry in paraffin section: 5-20ug/mL<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Colony Stimulating Factor Receptor, Granulocyte (GCSFR) | RPB476Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||